L-902688

Names

[ Name ]:
L-902688

[Synonym ]:
(5R)-5-[(1E,3R)-4,4-Difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-2-pyrrolidinone
2-Pyrrolidinone, 5-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-, (5R)-
l-902,688
2-Pyrrolidinone, 5-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-
5-[(1E,3R)-4,4-Difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5-yl)hexyl]-2-pyrrolidinone

Biological Activity

[Description]:

L-902688 is a potent, selective and orally active EP4 receptor agonist with a Ki of 0.38 nM and an EC50 of 0.6 nM. L-902688 shows >4,000-fold selective for EP4 over other EP and prostanoid receptors[1][2].

[Related Catalog]:

Research Areas >> Cardiovascular Disease

Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor

Research Areas >> Inflammation/Immunology

[Target]

EP4:0.38 nM (Ki)

EP4:0.6 nM (EC50)

[In Vitro]

L-902688 (1 µM; 24 hours; HUVE cells) treatment attenuates TGF-β-induced Twist and α-smooth muscle actin (α-SMA) expression[1]. Western Blot Analysis[1] Cell Line: Human umbilical vein endothelial cells (HUVECs) Concentration: 1 µM Incubation Time: 24 hours Result: Attenuated TGF-β-induced Twist and α-smooth muscle actin (α-SMA) expression.

[In Vivo]

L-902688 (0.25-1 µg/kg/day; intraperitoneal injection; daily; for 3 weeks; adult male Sprague-Dawley rats) treatment reduces right ventricle fibrosis in the monocrotaline (MCT)-induced PAH rat model[1]. Animal Model: Adult male Sprague-Dawley rats injected with crotaline to induce pulmonary arterial hypertension (PAH) and right ventricular (RV) hypertrophy[1] Dosage: 0.25 µg/kg/day, 0.4 µg/kg/day or 1 µg/kg/day Administration: Intraperitoneal injection; daily; for 3 weeks Result: Reduced right ventricle fibrosis in the monocrotaline (MCT)-induced PAH rat model.

[References]

[1]. Lai YJ, et al. EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension. Int J Mol Sci. 2018 Mar 3;19(3). pii: E727.

[2]. [2]Young, R.N., Billot, X., Han, Y., et al. Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist. Heterocycles. 2004, 64, 437-445.

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
645.8±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₁H₂₇F₂N₅O₂

[ Molecular Weight ]:
419.468

[ Flash Point ]:
344.4±34.3 °C

[ Exact Mass ]:
419.213287

[ PSA ]:
95.00000

[ LogP ]:
2.49

[ Vapour Pressure ]:
0.0±2.0 mmHg at 25°C

[ Index of Refraction ]:
1.597

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.